Pfizer's Net Income Drops in Q1. Is Its Dividend Still Safe?
Key takeaways
- That s considerably higher than the lowly S&P 500 average of just 1.1%.
- Thus, the incentive for income investors to buy Pfizer stock is high.
- Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need.
David Jagielski, CPA, The Motley Fool Tue, May 12, 2026 at 4:35 PM GMT+7 3 min read PFE ^GSPC One of the best reasons to invest in Pfizer (NYSE: PFE) stock right now is for its dividend, which yields a mouth-watering rate of 6.7%. That s considerably higher than the lowly S&P 500 average of just 1.1%. To put that in terms of dollars, a $25,000 investment in Pfizer stock could generate nearly $1,700 in annual dividend income (versus less than $300 if you went with the average S&P 500 stock).
Thus, the incentive for income investors to buy Pfizer stock is high. But others will argue that so too is the risk. And those fears may be heightened after the company posted its most recent earnings numbers, with net income falling from the previous year. Is Pfizer s dividend in danger, or does this still look like a compelling income investment?
Will AI create the world s first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »